Literature DB >> 22751280

Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.

Isabelle Ray-Coquard, David Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22751280     DOI： 10.1038/nrclinonc.2012.113

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; J-Y Blay
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

3.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Authors:  Nicolas Penel; Binh Nguyen Bui; Jacques-Olivier Bay; Didier Cupissol; Isabelle Ray-Coquard; Sophie Piperno-Neumann; Pierre Kerbrat; Charles Fournier; Sophie Taieb; Marta Jimenez; Nicolas Isambert; Frédéric Peyrade; Christine Chevreau; Emmanuelle Bompas; Etienne G C Brain; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 4.  Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.

Authors:  John R Mackey; Robert S Kerbel; Karen A Gelmon; Deanna M McLeod; Stephen K Chia; Daniel Rayson; Sunil Verma; Loretta L Collins; Alexander H G Paterson; André Robidoux; Kathleen I Pritchard
Journal:  Cancer Treat Rev       Date:  2012-02-23       Impact factor: 12.111

5.  Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Authors:  A Le Cesne; J Y Blay; I Judson; A Van Oosterom; J Verweij; J Radford; P Lorigan; S Rodenhuis; I Ray-Coquard; S Bonvalot; F Collin; J Jimeno; E Di Paola; M Van Glabbeke; O S Nielsen
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

6.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

Authors:  Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Authors:  Stefan Sleijfer; Isabelle Ray-Coquard; Zsuzsa Papai; Axel Le Cesne; Michelle Scurr; Patrick Schöffski; Françoise Collin; Lini Pandite; Sandrine Marreaud; Annick De Brauwer; Martine van Glabbeke; Jaap Verweij; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.

Authors:  Piotr Rutkowski; Janina Kaminska; Maria Kowalska; Wlodzimierz Ruka; Jan Steffen
Journal:  Int J Cancer       Date:  2002-08-01       Impact factor: 7.396

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544
  10 in total
  3 in total

1.  Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.

Authors:  Marc Becker; Claudine Graf; Marcus Tonak; Markus P Radsak; Tobias Bopp; Robert Bals; Rainer M Bohle; Matthias Theobald; Pol-Maria Rommens; Dirk Proschek; Thomas C Wehler
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

Review 2.  Pazopanib in sarcomas: expanding the PALETTE.

Authors:  Breelyn A Wilky; Christian F Meyer; Jonathan C Trent
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

3.  Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Authors:  Fadzai Chinyengetere; David J Sekula; Yun Lu; Andrew J Giustini; Aarti Sanglikar; Masanori Kawakami; Tian Ma; Sandra S Burkett; Burton L Eisenberg; Wendy A Wells; Paul J Hoopes; Elizabeth G Demicco; Alexander J Lazar; Keila E Torres; Vincent Memoli; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.